NasdaqGS:TEMLife Sciences
Tempus AI (TEM) Valuation Check After 2025 Results And New Cancer Care Partnerships
Tempus AI (TEM) is back in focus after preliminary 2025 results and fresh hospital partnerships drew investor attention, with revenue of about US$1.27b, record contract value above US$1.1b, and expanding oncology collaborations.
See our latest analysis for Tempus AI.
Despite a 1-year total shareholder return of about 111%, recent momentum has cooled, with a 90-day share price decline of 26.94% to US$67.15, as the market digests 2025 results and new hospital collaborations.
If Tempus AI has...